News
Appeal finds NICE must reconsider Alzheimer's drugs
Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
Sales & Marketing
Sponsored
Using AI-driven synthetic personas to take your insights fur...
As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
Market Access
12 questions with: Daniel Kohlstaedt
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
Digital
Sponsored
Expert Directed Applied Intelligence: Redefining AI in Life ...
In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.
R&D
Treating genetic disease at scale with tRNA, with Michelle W...
Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.
Digital
Sponsored
Data managers and CRAs warn of rising data quality risks due...
A new industry report uncovers the scope of a long-ignored problem in clinical trial operations.
R&D
Partner Content
Emerging Trends in Personalised Medicine at PHARMAP 2026
The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines